Navigation Links
AxoGen, Inc. Appoints Shawn McCarrey as Vice President of Sales
Date:3/5/2013

Alachua, FL (PRWEB) March 05, 2013

AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today the appointment of Shawn McCarrey to the position of Senior Vice President of Sales, effective immediately. In this role, Mr. McCarrey will participate in the implementation of the Company’s strategic growth initiatives and will lead AxoGen’s sales organization in the United States.

“We are now transitioning into the next phase of the Company’s growth, moving from early adopters to broad usage in surgical peripheral nerve repair,” said Karen Zaderej, Chief Executive Officer of AxoGen. “Shawn’s many years of experience and strong track record of success growing sales of early stage medical technologies will enhance AxoGen’s capabilities and accelerate adoption.    With a strong management team in place and the addition of resources from our recent PDL funding, we are well positioned to drive growth in the peripheral nerve repair market.”
Mr. McCarrey brings to AxoGen more than 15 years of experience as a national medical device sales executive. He most recently served as Executive Vice President of North American Cardiovascular Sales at Bayer Interventional/MEDRAD Interventional. From 1998 through 2009, Mr. McCarrey was rapidly promoted through the executive ranks at Possis Medical, an early commercial stage cardio- and peripheral-vascular company ultimately acquired by MEDRAD Interventional, culminating with his appointment as EVP of Worldwide Sales & Marketing. Earlier in his career, Mr. McCarrey served in sales and sales leadership roles in the Davol and USCI divisions of C.R. Bard.

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa EMC product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10497195.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
2. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
3. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
4. U.N. Secretary-General Appoints Ray Chambers as His First Special Envoy for the Financing of the Health-Related Millennium Development Goals
5. Private Real Estate Investment Firm, Cohen Asset Management, Inc., Appoints Senior Vice President of Asset Management for East Coast
6. Dynarex Corporation Appoints a New National Sales Manager to Lead their Sales Organization
7. PaloDEx Appoints Brian Broncatti to the Position of Vice President North America
8. Life Support Technologies Group Appoints Edward Golembe, MD as Co-Clinical Director
9. Life Support Technologies Group Appoints Scott Gorenstein, MD as Co-Clinical Director
10. EPC Group Appoints Industry Veteran to Lead Development Practice Expansion
11. Eagle Village Appoints Mike Mischley and Dani Montini to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
Breaking Medicine Technology: